btrx-335140
Small moleculeexperimental
Clinical trial activity
6 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
6
Phase 3
4
Phase 4
0
Earliest trial started Jan 31, 2020 (NCT04221230)
Timeline
Indications
Studied for
Mechanism of action
- Kappa opioid receptorANTAGONIST
OPRK1 antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06429722 | Phase 2 | May 13, 2024 | Neumora Therapeutics, Inc. |
| NCT06058013 | Phase 3 | Nov 30, 2023 | Neumora Therapeutics, Inc. |
| NCT06058039 | Phase 3 | Nov 30, 2023 | Neumora Therapeutics, Inc. |
| NCT06029439 | Phase 3 | Nov 10, 2023 | Neumora Therapeutics, Inc. |
| NCT06029426 | Phase 3 | Sep 20, 2023 | Neumora Therapeutics, Inc. |
| NCT04221230 | Phase 2 | Jan 31, 2020 | Neumora Therapeutics, Inc. |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Neumora Therapeutics, Inc. | For profit | 6 | 6 | 2 | 2020 |
1 organizations
Page 1 / 1